JP2002504091A - コルチコステロイドに対する応答性を調整するための方法及び組成物 - Google Patents

コルチコステロイドに対する応答性を調整するための方法及び組成物

Info

Publication number
JP2002504091A
JP2002504091A JP54063398A JP54063398A JP2002504091A JP 2002504091 A JP2002504091 A JP 2002504091A JP 54063398 A JP54063398 A JP 54063398A JP 54063398 A JP54063398 A JP 54063398A JP 2002504091 A JP2002504091 A JP 2002504091A
Authority
JP
Japan
Prior art keywords
patient
corticosteroids
patients
acid
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP54063398A
Other languages
English (en)
Japanese (ja)
Inventor
セクート，レス
カーター，アダム
ガユル，タリク
バーナジー，スバシス
イー． トレイシー，ダニエル
Original Assignee
ベーアーエスエフ アクツィエンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/820,692 external-priority patent/US6054487A/en
Application filed by ベーアーエスエフ アクツィエンゲゼルシャフト filed Critical ベーアーエスエフ アクツィエンゲゼルシャフト
Publication of JP2002504091A publication Critical patent/JP2002504091A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
JP54063398A 1997-03-18 1998-03-12 コルチコステロイドに対する応答性を調整するための方法及び組成物 Pending JP2002504091A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/820,692 US6054487A (en) 1997-03-18 1997-03-18 Methods and compositions for modulating responsiveness to corticosteroids
US08/820,692 1997-03-18
US1634698A 1998-01-30 1998-01-30
PCT/US1998/004916 WO1998041232A2 (en) 1997-03-18 1998-03-12 Compositions for modulating responsiveness to corticosteroids
US09/016,346 1998-10-30

Publications (1)

Publication Number Publication Date
JP2002504091A true JP2002504091A (ja) 2002-02-05

Family

ID=26688484

Family Applications (1)

Application Number Title Priority Date Filing Date
JP54063398A Pending JP2002504091A (ja) 1997-03-18 1998-03-12 コルチコステロイドに対する応答性を調整するための方法及び組成物

Country Status (20)

Country Link
EP (1) EP0998300A1 (hu)
JP (1) JP2002504091A (hu)
KR (1) KR20000076420A (hu)
CN (1) CN1269722A (hu)
AU (1) AU734756B2 (hu)
BG (1) BG103808A (hu)
BR (1) BR9810409A (hu)
CA (1) CA2282845A1 (hu)
DE (1) DE998300T1 (hu)
ES (1) ES2146192T1 (hu)
HU (1) HUP0104439A3 (hu)
ID (1) ID22975A (hu)
IL (1) IL131815A0 (hu)
NO (1) NO994506L (hu)
NZ (1) NZ337769A (hu)
PL (1) PL336464A1 (hu)
SI (1) SI20110A (hu)
SK (1) SK122199A3 (hu)
TR (1) TR199902615T2 (hu)
WO (1) WO1998041232A2 (hu)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005110450A1 (ja) * 2004-05-17 2005-11-24 Keio University 医薬組成物及び治療方法
WO2006009114A1 (ja) * 2004-07-16 2006-01-26 Atsuo Sekiyama Ｉｌ－１８レセプターアンタゴニスト、および当該アンタゴニストを含む薬学的組成物
JP2006503905A (ja) * 2002-09-24 2006-02-02 コンビナトアールエックス インコーポレーティッド 炎症性サイトカインのレベルの増大と関連する病気および障害の治療のための方法および試薬
WO2006041121A1 (ja) * 2004-10-13 2006-04-20 Kyowa Hakko Kogyo Co., Ltd. 慢性皮膚疾患の治療および／または予防剤
JP2015155423A (ja) * 2006-10-17 2015-08-27 ネオセティクス，インク． 甲状腺眼症の治療のための方法、組成物及び製剤

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6830751B1 (en) 1994-03-14 2004-12-14 Genetics Institute, Llc Use of IL-12 antagonists in the treatment of rheumatoid arthritis
ZA95960B (en) * 1994-03-14 1995-10-10 Genetics Inst Use of interleukin-12 antagonists in the treatment of autoimmune diseases
US7704944B2 (en) 1997-08-14 2010-04-27 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis
IL121860A0 (en) 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
US7220717B2 (en) 1997-08-14 2007-05-22 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use
US6184210B1 (en) 1997-10-10 2001-02-06 Cytovia, Inc. Dipeptide apoptosis inhibitors and the use thereof
AR015966A1 (es) * 1997-10-17 2001-05-30 Smithkline Beecham Corp Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito
DE69825976T2 (de) * 1997-10-31 2005-09-01 Wyeth Verwendung von anti-il-12 antikörpern bei transplantationsabstossungen
EP1516630A3 (en) * 1997-10-31 2006-05-03 Wyeth Use of anti-il-12 antibodies in transplantation rejection
WO1999025737A1 (en) * 1997-11-19 1999-05-27 Tanox Pharma B.V. Compositions and methods for treatment of autoimmune diseases, using a monoclonal antibody to the interleukin-12 beta2-chain
AU755273B2 (en) * 1998-03-16 2002-12-05 Cytovia, Inc. Dipeptide caspase inhibitors and the use thereof
CA2355345A1 (en) * 1998-11-27 2001-06-28 Technion Research & Development Foundation Ltd. Interferon gamma inducing factor based vaccine and use of same for protective immunity against multiple sclerosis
JP3579355B2 (ja) * 1998-12-09 2004-10-20 プロテイン デザイン ラブス インコーポレイティド ヒトの乾癬を予防及び治療するための乾癬モデル動物
CA2367340A1 (en) 1999-03-16 2000-09-21 Cytovia, Inc. Substituted 2-aminobenzamide caspase inhibitors and the use thereof
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US7883704B2 (en) 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
DE19915465A1 (de) * 1999-04-06 2000-10-19 Apotech Res & Dev Ltd Verwendung eines Caspase-Inhibitors zur Proliferationshemmung von Zellen und Verwendung eines oder mehrerer Caspase-Inhibitors/en zur Behandlung von Erkrankungen beruhend auf Lymphozyten-Hyperproliferation oder zur Suppression einer Immunantwort durch Lymphozyten
CA2369619A1 (en) 1999-04-09 2000-10-19 Cytovia, Inc. Caspase inhibitors and the use thereof
IL131047A0 (en) * 1999-07-22 2001-01-28 Yeda Res & Dev Use of il-18 inhibitors
JP2003508379A (ja) 1999-08-27 2003-03-04 サイトビア インコーポレイテッド 置換α−ヒドロキシ酸カスパーゼインヒビターおよびその使用
AU7127600A (en) * 1999-09-17 2001-04-17 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
US6566338B1 (en) 1999-10-12 2003-05-20 Cytovia, Inc. Caspase inhibitors for the treatment and prevention of chemotherapy and radiation therapy induced cell death
TWI373343B (en) 2000-02-10 2012-10-01 Abbott Gmbh & Co Kg Antibodies that bind human interleukin-18 and methods of making and using
ES2267778T3 (es) * 2000-06-06 2007-03-16 Glaxo Group Limited Composicion para el tratamiento del cancer, que contiene un agente anti-neoplastico y un inhibidor de pde4.
WO2001097815A2 (de) * 2000-06-22 2001-12-27 Willy Ben Moussa Ben Mohammed Verwendung von glukokortikosteroiden zur herstellung eines medikamentes für die behandlung von haarschwund
US20020025317A1 (en) * 2000-07-20 2002-02-28 Schering Ag Bispecific monoclonal antibodies to IL-12 and IL-18
WO2002022127A1 (en) * 2000-09-13 2002-03-21 Isis Innovation Limited Use of phosphodiesterase inhibitors for the treatment of anorectal disorders
EP1199074A1 (en) * 2000-09-15 2002-04-24 Warner-Lambert Company Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production
EP1188438A1 (en) * 2000-09-15 2002-03-20 Warner-Lambert Company Pharmaceutical composition for preventing or treating a disease associated with an excess of Il-12 production
ME00549B (me) * 2001-01-29 2011-10-10 Serono Lab Upotreba inhibitora il-18 za liječenje i/ili prevenciju srčanih oboljenja
EA009125B1 (ru) * 2001-05-16 2007-10-26 Йеда Рисерч Энд Дивелопмент Ко., Лтд. Применение ингибиторов il-18 для лечения и/или предупреждения заболеваний, характерных для синдрома системной воспалительной реакции
NZ547695A (en) 2001-06-26 2008-09-26 Amgen Fremont Inc Antibodies to OPGL
AR036741A1 (es) * 2001-10-05 2004-09-29 Combinatorx Inc Combinaciones para el tratamiento de los trastornos inmunoinflamatorios
JP2003342196A (ja) * 2002-05-31 2003-12-03 Mukku:Kk 静脈注射用組成物、その製造法およびその製剤
WO2004028545A1 (en) * 2002-09-25 2004-04-08 Astrazeneca Ab A COMBINATION OF A LONG-ACTING β2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES
US20060083714A1 (en) * 2003-01-27 2006-04-20 Warner James M Combination of a pde iv inhibitor and a tnf-alpha antagonist
US20050100965A1 (en) 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
CA2615173C (en) 2005-07-14 2012-01-03 Lipothera, Inc. Sustained release enhanced lipolytic formulation for regional adipose tissue treatment
KR20150038227A (ko) 2007-01-16 2015-04-08 애브비 인코포레이티드 건선의 치료방법
WO2008121301A1 (en) 2007-03-29 2008-10-09 Abbott Laboratories Crystalline anti-human il-12 antibodies
AU2009225797A1 (en) 2008-03-18 2009-09-24 Abbvie Inc. Methods for treating psoriasis
US9132084B2 (en) 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
US9597531B2 (en) 2010-11-24 2017-03-21 Neothetics, Inc. Selective, lipophilic, and long-acting beta agonist monotherapeutic formulations and methods for the cosmetic treatment of adiposity and contour bulging
WO2015063669A1 (en) 2013-10-30 2015-05-07 Wockhardt Limited Pharmaceutical compositions comprising combination of roflumilast and acebrophylline or pharmaceutically acceptable salts thereof
WO2023049809A1 (en) * 2021-09-22 2023-03-30 Iolyx Therapeutics, Inc. Methods of treating ocular inflammatory diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3320125A (en) * 1964-04-28 1967-05-16 Merck & Co Inc Inhalation aerosol composition
DK0416950T3 (da) * 1989-09-08 1993-10-11 Glaxo Group Ltd Medikamenter
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant
GB9202519D0 (en) * 1992-02-06 1992-03-25 Glaxo Group Ltd Medicaments
MX9304585A (es) * 1992-07-31 1994-03-31 Glaxo Group Ltd Formulacion farmaceutica en aerosol, lata adecuada para liberar la formulacion e inhalador de dosis dosificada que comprende la lata.
GB9426252D0 (en) * 1994-12-24 1995-02-22 Glaxo Group Ltd Pharmaceutical composition
US6149892A (en) * 1995-04-14 2000-11-21 Glaxowellcome, Inc. Metered dose inhaler for beclomethasone dipropionate

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006503905A (ja) * 2002-09-24 2006-02-02 コンビナトアールエックス インコーポレーティッド 炎症性サイトカインのレベルの増大と関連する病気および障害の治療のための方法および試薬
WO2005110450A1 (ja) * 2004-05-17 2005-11-24 Keio University 医薬組成物及び治療方法
WO2006009114A1 (ja) * 2004-07-16 2006-01-26 Atsuo Sekiyama Ｉｌ－１８レセプターアンタゴニスト、および当該アンタゴニストを含む薬学的組成物
US7887802B2 (en) 2004-07-16 2011-02-15 Atsuo Sekiyama IL-18 receptor antagonist and pharmaceutical composition containing the antagonist
WO2006041121A1 (ja) * 2004-10-13 2006-04-20 Kyowa Hakko Kogyo Co., Ltd. 慢性皮膚疾患の治療および／または予防剤
JP2015155423A (ja) * 2006-10-17 2015-08-27 ネオセティクス，インク． 甲状腺眼症の治療のための方法、組成物及び製剤
JP2015163612A (ja) * 2006-10-17 2015-09-10 ネオセティクス，インク． 甲状腺眼症の治療のための方法、組成物及び製剤

Also Published As

Publication number Publication date
AU734756B2 (en) 2001-06-21
HUP0104439A3 (en) 2002-08-28
CA2282845A1 (en) 1998-09-24
NO994506L (no) 1999-11-17
ES2146192T1 (es) 2000-08-01
WO1998041232A2 (en) 1998-09-24
SK122199A3 (en) 2000-12-11
TR199902615T2 (xx) 2000-03-21
BG103808A (en) 2000-07-31
KR20000076420A (ko) 2000-12-26
IL131815A0 (en) 2001-03-19
NO994506D0 (no) 1999-09-17
AU6760498A (en) 1998-10-12
ID22975A (id) 1999-12-23
BR9810409A (pt) 2000-08-22
SI20110A (sl) 2000-06-30
CN1269722A (zh) 2000-10-11
DE998300T1 (de) 2001-03-01
HUP0104439A2 (hu) 2002-04-29
EP0998300A1 (en) 2000-05-10
NZ337769A (en) 2002-09-27
WO1998041232A3 (en) 2000-10-05
PL336464A1 (en) 2000-06-19

Similar Documents

Publication Publication Date Title
JP2002504091A (ja) コルチコステロイドに対する応答性を調整するための方法及び組成物
US6054487A (en) Methods and compositions for modulating responsiveness to corticosteroids
ES2323159T3 (es) Compuestos con propiedades de liberacion de la hormona del crecimiento.
JP4504570B2 (ja) 炭素環式カリウムチャンネル阻害薬
JP4676676B2 (ja) カスパーゼ阻害剤としての複素環ジカルバミド
JPH10501244A (ja) インターロイキン−１β変換酵素の二環式ラクタム阻害剤
JPH09511249A (ja) インターロイキン阻害剤としてのピリミジニル誘導体
WO2001019373A2 (en) Methods and compositions for modulating responsiveness to corticosteroids
JP2001517246A (ja) α▲下４▼β▲下１▼媒介細胞接着の阻止剤
JP2002502873A (ja) 化合物
KR20000064454A (ko) 인터류킨-1베타전환효소의억제제
JP2001518922A (ja) アリール−またはヘテロアリール−スルホンアミドで置換されたヒドロキサム酸誘導体、その製法およびその医薬としての使用
JP2002509153A (ja) インターロイキン−１β変換酵素（ＩＣＥ）のインビボ阻害剤としてのＮ−［２−（５−ベンジルオキシカルボニル−アミノ−６−オキソ−２−（４−フルオロフェニル）−１，６−ジヒドロ−１−ピリミジニル）アセトキシル］−Ｌ−アスパラギン酸アルデヒド
TW201802110A (zh) 新穎環孢素衍生物及其用途
JP2000508666A (ja) 成長ホルモン放出特性を有する化合物
JPH11511481A (ja) 免疫抑制活性を有するトリテルペン誘導体
JP2003532727A (ja) Ｃｄ２３の阻害剤としてのｎ−スルホニルヒドロキサム酸誘導体
JP3922431B2 (ja) 可溶性ヒトｃｄ２３形成阻害剤としてのヒドロキサム酸誘導体
JP4181220B2 (ja) Ｉｌ―４およびｇ―ｃｓｆに影響するナフチリジン類
JP2021523138A (ja) Ｉｌ−２３抗体を使用してうつを治療する方法
JPH08511783A (ja) Ｎ−置換アザ複素環式カルボン酸類とそのエステル類
JPH06271533A (ja) 免疫抑制剤としての新規なアミノメチレン誘導体
CZ312799A3 (cs) Přípravky pro modulaci reakce na kortikosteroidy
MXPA99008433A (en) Methods and compositions for modulating responsiveness to corticosteroids
JP2003012626A (ja) アルキルアミド化合物